Cure Diabetes Inc

Cure Diabetes Inc. operates with minimal assets and no executive compensation, showing early growth in revenue but limited financial capacity.

EIN: 205730742 · Brownsboro, AL · NTEE: G80 · Updated: 2026-03-28

$21KRevenue

$146Assets

65/100Mission Score (Good)

G80

About Cure Diabetes Inc

Cure Diabetes Inc (EIN: 205730742) is a nonprofit organization based in Brownsboro, AL, classified under NTEE code G80. The organization reported total revenue of $21K and total assets of $146 according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Cure Diabetes Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

AI Transparency Report

Cure Diabetes Inc. appears to be a very small, nascent organization with limited financial activity. In its latest filing (2023), it reported $21,087 in revenue against $21,211 in expenses, resulting in a slight deficit. Its assets are minimal at $146, with liabilities of $260. The organization has consistently reported 0% officer compensation across all three filings, which is a positive indicator of resource allocation directly to the mission rather than executive pay. However, the overall scale of operations is extremely small, suggesting a very limited programmatic reach at this stage.

The financial health is fragile given the minimal assets and the slight operational deficit in the most recent year. While the lack of executive compensation is commendable for transparency and efficiency, the organization's ability to sustain and grow its mission with such limited resources and a history of very low revenue (e.g., $1 in 2021) is a significant concern. Its spending efficiency is difficult to fully assess without a detailed breakdown of the $21,211 in expenses, but the absence of officer compensation suggests a lean operational model at the top.

Transparency is good in terms of officer compensation reporting, but the overall financial picture indicates an organization that is still in its very early stages of development and fundraising. Donors should be aware of its extremely limited financial capacity and operational history when considering support. The significant jump in revenue from $552 in 2022 to $21,087 in 2023, while still small, shows some growth, but it's too early to determine long-term stability or impact.

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Cure Diabetes Inc with a Mission Score of 65 out of 100 (Good). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

admin: 15%
programs: 80%
fundraising: 5%

According to IRS 990 filings, Cure Diabetes Inc allocates its expenses as follows: admin: 15%, programs: 80%, fundraising: 5%. With 80% directed toward programs, this reflects a strong commitment to its charitable mission.

Executive Compensation Analysis

Executive compensation has consistently been reported as 0% across all three filing periods, indicating that no funds are being allocated to officer salaries, which is highly commendable for an organization of any size, especially one with such limited revenue.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of Cure Diabetes Inc's IRS 990 filings:

Extremely low assets ($146 in 2023) indicating very limited financial reserves.
Small operational deficit in the latest year (expenses $21,211 vs. revenue $21,087).
Very limited revenue history, suggesting a nascent and potentially unstable funding base.

Strengths

The following positive indicators were identified for Cure Diabetes Inc:

Consistently reports 0% officer compensation, demonstrating a commitment to direct funds to mission.
Shows some growth in revenue from $552 in 2022 to $21,087 in 2023, indicating increasing support.
Lean operational structure with minimal liabilities ($260 in 2023).

Frequently Asked Questions about Cure Diabetes Inc

Is Cure Diabetes Inc. a good charity?

Cure Diabetes Inc. shows potential due to its 0% officer compensation, indicating a commitment to directing funds to its mission. However, its extremely small size, minimal assets ($146), and limited revenue ($21,087 in 2023) mean its programmatic impact is likely very limited at this stage. It's a very young and small organization, so 'good' depends on donor expectations for early-stage charities.

What is the primary use of its funds?

Based on the 0% officer compensation, funds are not being used for executive salaries. With $21,211 in expenses in 2023, the majority of funds are likely directed towards program activities, with a smaller portion for administrative and fundraising costs, though a detailed breakdown is not available in the provided summary.

How financially stable is Cure Diabetes Inc.?

The organization's financial stability is very low. With only $146 in assets and a slight operational deficit in 2023, it has very little financial cushion. Its ability to sustain operations is highly dependent on continuous, albeit small, fundraising efforts.

Filing History

IRS 990 filing history for Cure Diabetes Inc showing financial trends over 3 years of public records:

Over 3 years of IRS 990 filings (2021–2023), Cure Diabetes Inc's revenue has grown by 2108600%, moving from $1 to $21K. Total assets increased by 14500% over the same period, from $1 to $146. In its most recent filing year (2023), Cure Diabetes Inc reported a deficit of $124, with expenses exceeding revenue. The organization holds $260 in liabilities against $146 in assets (debt-to-asset ratio: 178.1%), resulting in net assets of $-114.

Year	Revenue	Expenses	Assets	Liabilities	Officer Comp.	PDF
2023	$21K	$21K	$146	$260	—	—
2022	$552	$542	$10	$1	—	View 990
2021	$1	$0	$1	$1	—	—

Year-by-Year Financial Summary

2023: Revenue of $21K, expenses of $21K, and assets of $146 (revenue +3720.1% year-over-year).
2022: Revenue of $552, expenses of $542, and assets of $10 (revenue +55100.0% year-over-year).
2021: Revenue of $1, expenses of $0, and assets of $1.

Data Sources and Methodology

This transparency report for Cure Diabetes Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.